Drug
Inca33890
Inca33890: highest development phase Phase 3, developed by Incyte. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| INCA33890 NCT07284849 | Phase 3 | CRC (Colorectal Cancer) |
Latest
No recent events.
Follow Inca33890 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.